NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









InterVenn Biosciences

InterVenn Biosciences

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://intervenn.com/

Last Round

Series C

Aug 2, 2021

Total Funding Raised

$244.4M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

InterVenn Biosciences is a biotechnology company that develops an AI-powered platform for glycoproteomic analysis to enhance early cancer detection and precision medicine.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical AI, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

glycoproteomicsliquid biopsybiomarker discoverycancer diagnosticsclinical laboratoryCLIA labprecision oncologyAI diagnosticsnon-invasive testingmulti-omicslaboratory developed testLDTbiotech platformmass spectrometrydiagnostic AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

InterVenn Biosciences Comps

Public and private peers based on sector, stage, and business model.

InterVenn Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

InterVenn Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CAug 2, 2021
Series BNov 16, 2020
Series ADec 12, 2018

Key People

Founding team and executive leadership

Andrew Quong

President and CEO

Executive Team

Peter S.

Chief Financial Officer

Executive Team

David King

Chief Operating Officer

Executive Team

InterVenn Biosciences Investors

Notable investors and investment history

InterVenn Biosciences investors
InvestorRounds
Xeraya CapitalSeries B, Series C
Ojjeh FamilySeries B
Highside Capital ManagementSeries C
Prado SVSeries A
SoftBank GroupSeries C
Genoa VenturesSeries B, Series C, Series A
Irving InvestorsSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 25, 2026

    Grew 21% QoQ, from 39 to 47 employees.

  • Mar 18, 2025

    Andrew Quong appointed as the new Chief Executive Officer.

InterVenn Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

InterVenn Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about InterVenn Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range48
Year Founded2017
Last FundingAug 2, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.